Kaliumchloride + Glucose B. Braun (Potassium Chloride, Glucose)

Potassium chloride dissociates in the bloodstream, releasing potassium ions that are taken up by cells via the Na⁺/K⁺‑ATPase pump. This restores normal cellular membrane potential, supports muscle contraction, and helps maintain cardiac rhythm. The accompanying glucose is metabolized for immediate energy and helps maintain osmotic equilibrium.

The dose is individualized by the prescribing clinician based on the patient’s serum potassium level, renal function, and overall clinical condition. Healthcare professionals calculate the required potassium and glucose amounts and set the infusion rate according to institutional protocols.

Safety data are limited, and the product should be used in pregnancy or lactation only if the potential benefit justifies any potential risk to the fetus or infant. Clinicians must evaluate the maternal condition and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and required import documentation.

Kaliumchloride + Glucose B. Braun combines potassium chloride with glucose, offering both electrolyte correction and an energy source in a single infusion. Compared with potassium chloride alone, it reduces the need for separate glucose administration, simplifying fluid management in critically ill patients.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required by the administration protocol.

It is administered intravenously by slow infusion, typically through a peripheral or central line. The infusion rate is determined by the prescribing clinician, taking into account the patient’s potassium deficit, glucose needs, and overall fluid balance.

The most serious risks include severe hyperkalemia, which can cause life‑threatening cardiac arrhythmias, and rare allergic reactions such as anaphylaxis. Monitoring of serum potassium, ECG, and blood glucose is essential to detect and manage these risks promptly.

Patients with known hypersensitivity to potassium chloride, glucose, or any excipients in the formulation should avoid this product. It is also contraindicated in individuals with severe hyperkalemia, uncontrolled diabetes mellitus, or those for whom rapid potassium infusion poses a high cardiac risk.